Medtech Insight

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

By Shawn M. Schmitt 14 Nov 2022

Toyota Motor North America's Kristen Tabar told a roomful of medical device quality and regulatory professionals at a Case for Quality forum that they can infuse quality concepts into every nook and cranny of their firms by adopting the car-maker's quality strategy of reflection, education, celebration and planning. "I don’t want to make it sound like it’s sort of cult-y, but it’s kind of cult-y," Tabar quipped.

Topic Company Analysis Strategy

In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 14 Nov 2022

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

Scrip

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

By Jung Won Shin 25 Oct 2022

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

Topic Company Analysis Strategy

In Vivo

ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

By William Looney 27 Nov 2020

The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Topic Financing Strategy

Generics Bulletin

Biocon Biologics Gets True North Investment

By Vibha Ravi 27 Nov 2020

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

In Vivo

COVID-19: Global Perspective Infographic

21 Jul 2020

Your snapshot view of how the life sciences in nations around the globe are responding to the COVID-19 pandemic is now available. Register today to receive your free World Vision 360° infographic from In Vivo. 

Topic Strategy Research & Development

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deals Strategy

Generics Bulletin

Teva Debuts US Rituximab At A 10% Discount

By David Wallace 08 Nov 2019

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Topic Biosimilars Strategy

Meddevicetracker

Introducing Meddevicetracker's Market Analysis Tool

02 Aug 2019

Find and manipulate the essential medical devices and diagnostics market intelligence you rely on from Meddevicetracker’s Market Analysis Reports with Meddevicetracker’s new interactive Market Analysis tool. 

Topic Strategy Business Strategies Company Analysis